vs
Side-by-side financial comparison of CB Financial Services, Inc. (CBFV) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
CB Financial Services, Inc. is the larger business by last-quarter revenue ($13.8M vs $9.1M, roughly 1.5× Protalix BioTherapeutics, Inc.). On growth, CB Financial Services, Inc. posted the faster year-over-year revenue change (19.9% vs -49.9%). CB Financial Services, Inc. produced more free cash flow last quarter ($17.2M vs $1.6M). Over the past eight quarters, CB Financial Services, Inc.'s revenue compounded faster (1.2% CAGR vs -6.7%).
CB Bank is one of Myanmar's largest commercial banks. It became the first bank in Myanmar to issue ATM cards and credit cards. The bank, led by U Khin Maung Aye (Chairman) and U Kyaw Thu Ko (CEO) has over 245 branches across the country.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
CBFV vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $9.1M |
| Net Profit | — | $-5.5M |
| Gross Margin | — | 49.4% |
| Operating Margin | 38.1% | -51.1% |
| Net Margin | — | -60.3% |
| Revenue YoY | 19.9% | -49.9% |
| Net Profit YoY | — | -184.8% |
| EPS (diluted) | $0.90 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | $9.1M | ||
| Q3 25 | $2.4M | $17.9M | ||
| Q2 25 | $13.5M | $15.7M | ||
| Q1 25 | $12.1M | $10.1M | ||
| Q4 24 | $13.2M | $18.2M | ||
| Q3 24 | $12.7M | $18.0M | ||
| Q2 24 | $12.2M | $13.5M | ||
| Q1 24 | $13.5M | — |
| Q4 25 | — | $-5.5M | ||
| Q3 25 | $-5.7M | $2.4M | ||
| Q2 25 | $3.9M | $164.0K | ||
| Q1 25 | $1.9M | $-3.6M | ||
| Q4 24 | — | $6.5M | ||
| Q3 24 | $3.2M | $3.2M | ||
| Q2 24 | $2.6M | $-2.2M | ||
| Q1 24 | $4.2M | — |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
| Q4 25 | 38.1% | -51.1% | ||
| Q3 25 | -289.8% | 11.9% | ||
| Q2 25 | 35.0% | 7.5% | ||
| Q1 25 | 19.3% | -41.0% | ||
| Q4 24 | 23.1% | 39.6% | ||
| Q3 24 | 31.2% | 22.2% | ||
| Q2 24 | 26.4% | -18.0% | ||
| Q1 24 | 37.9% | — |
| Q4 25 | — | -60.3% | ||
| Q3 25 | -235.2% | 13.2% | ||
| Q2 25 | 29.3% | 1.0% | ||
| Q1 25 | 15.8% | -35.8% | ||
| Q4 24 | — | 35.6% | ||
| Q3 24 | 25.3% | 18.0% | ||
| Q2 24 | 21.8% | -16.4% | ||
| Q1 24 | 31.1% | — |
| Q4 25 | $0.90 | $-0.06 | ||
| Q3 25 | $-1.07 | $0.03 | ||
| Q2 25 | $0.74 | $0.00 | ||
| Q1 25 | $0.35 | $-0.05 | ||
| Q4 24 | $0.45 | $0.10 | ||
| Q3 24 | $0.60 | $0.03 | ||
| Q2 24 | $0.51 | $-0.03 | ||
| Q1 24 | $0.82 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.7M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $157.5M | $48.2M |
| Total Assets | $1.5B | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.7M | $14.7M | ||
| Q3 25 | $55.9M | $13.6M | ||
| Q2 25 | $64.5M | $17.9M | ||
| Q1 25 | $61.3M | $19.5M | ||
| Q4 24 | $49.6M | $19.8M | ||
| Q3 24 | $147.3M | $27.4M | ||
| Q2 24 | $142.6M | $23.4M | ||
| Q1 24 | $73.7M | — |
| Q4 25 | $157.5M | $48.2M | ||
| Q3 25 | $152.5M | $52.9M | ||
| Q2 25 | $148.4M | $49.9M | ||
| Q1 25 | $148.3M | $45.2M | ||
| Q4 24 | $147.4M | $43.2M | ||
| Q3 24 | $149.1M | $32.4M | ||
| Q2 24 | $142.9M | $28.6M | ||
| Q1 24 | $141.6M | — |
| Q4 25 | $1.5B | $82.3M | ||
| Q3 25 | $1.5B | $82.3M | ||
| Q2 25 | $1.5B | $78.5M | ||
| Q1 25 | $1.5B | $73.9M | ||
| Q4 24 | $1.5B | $73.4M | ||
| Q3 24 | $1.6B | $61.6M | ||
| Q2 24 | $1.6B | $91.5M | ||
| Q1 24 | $1.5B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $17.8M | $2.0M |
| Free Cash FlowOCF − Capex | $17.2M | $1.6M |
| FCF MarginFCF / Revenue | 124.1% | 17.8% |
| Capex IntensityCapex / Revenue | 4.7% | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $29.5M | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $17.8M | $2.0M | ||
| Q3 25 | $4.6M | $-3.7M | ||
| Q2 25 | $4.1M | $-5.2M | ||
| Q1 25 | $4.0M | $-5.1M | ||
| Q4 24 | $6.8M | $4.0M | ||
| Q3 24 | $3.1M | $4.1M | ||
| Q2 24 | $-1.2M | $-3.6M | ||
| Q1 24 | $3.3M | — |
| Q4 25 | $17.2M | $1.6M | ||
| Q3 25 | $4.5M | $-4.2M | ||
| Q2 25 | $3.9M | $-5.7M | ||
| Q1 25 | $3.9M | $-5.4M | ||
| Q4 24 | $3.4M | $3.6M | ||
| Q3 24 | $2.2M | $4.0M | ||
| Q2 24 | $-2.4M | $-3.8M | ||
| Q1 24 | $2.3M | — |
| Q4 25 | 124.1% | 17.8% | ||
| Q3 25 | 186.5% | -23.7% | ||
| Q2 25 | 28.8% | -36.2% | ||
| Q1 25 | 32.5% | -53.0% | ||
| Q4 24 | 26.0% | 19.6% | ||
| Q3 24 | 17.4% | 22.4% | ||
| Q2 24 | -19.6% | -28.1% | ||
| Q1 24 | 17.0% | — |
| Q4 25 | 4.7% | 4.4% | ||
| Q3 25 | 4.3% | 2.8% | ||
| Q2 25 | 1.9% | 2.8% | ||
| Q1 25 | 0.8% | 3.0% | ||
| Q4 24 | 25.1% | 2.3% | ||
| Q3 24 | 6.7% | 0.5% | ||
| Q2 24 | 10.0% | 1.3% | ||
| Q1 24 | 7.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | 1.05× | -31.91× | ||
| Q1 25 | 2.11× | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | 0.95× | 1.27× | ||
| Q2 24 | -0.44× | — | ||
| Q1 24 | 0.78× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBFV
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
